PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma

PIK3CA mutations in cancer regulate tumour immunogenicity. Given that PIK3CA mutation subtypes influence therapeutic responses to AKT inhibitor and that H1047R mutation confers selective growth advantages after immunotherapy, we hypothesised that immune phenotypes may depend on PIK3CA mutation subtypes. We investigated 133 gastric cancers (GCs) harbouring PIK3CA mutation [21 E542K (15.8%), 36 E545X (27.1%), 26 H1047X (19.5%), and 46 others (34.6%)]. Four patients (3.0%) had a combination of mutations (E542K + E545K in 3 patients and E545K + H1047R in 1 patient). Epstein–Barr virus (EBV) and microsatellite instability (MSI) status, PD‐L1 (programmed death‐ligand 1) combined positive score (CPS), and stromal tumour‐infiltrating lymphocytes (TILs) were assessed. Concurrent genomic alterations, GeoMx digital spatial profiling (DSP), and OPAL multiplex immunohistochemistry (mIHC) were analysed, and correlation between the two assays was investigated. Of the 133 PIK3CA‐mutant (PIK3CAm) GCs, MSI‐high GC was significantly frequent in the H1047X mutation subtype (p = 0.005), while EBV positivity did not affect the mutation subtypes. There was no significant survival difference between the E542K, E545X, and H1047X subgroups. However, in the subgroup analysis for EBV‐positive GC, H1047Xm GC showed a trend towards shorter survival than E542K and E545Xm GC (p = 0.090 and 0.062). With DSP analysis, H1047Xm GC showed elevated VISTA (p = 0.0003), granzyme B (p < 0.0001), CD4 (p = 0.0001), and CD45 (p < 0.0001) expression compared with the E542Km or E545Xm GC subgroups, and only VISTA expression remained significant (p < 0.0001) using OPAL mIHC. DSP and OPAL analyses showed a moderate correlation of CD4 (ρ = 0.42, p = 0.004) and CD8 (ρ = 0.62, p < 0.001) expression levels in a comparison of six antibodies. Immune‐related protein expression levels were evident when classified by the three PIK3CA hotspot mutations, and H1047Xm GC showed the highest immune‐related protein expression compared with E542Km or E545Xm GC. Our results demonstrated distinct immune profiles in GC with PIK3CA hotspot mutations using GeoMx DSP and OPAL mIHC, and there was a correlation between the two multiplex platforms. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

[1]  J. Ji,et al.  Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis , 2022, Journal for ImmunoTherapy of Cancer.

[2]  S. Yao,et al.  Multiplexed digital spatial profiling of invasive breast tumors from Black and White women , 2021, Molecular oncology.

[3]  Doron Betel,et al.  Immunogenicity of a public neoantigen derived from mutated PIK3CA , 2021, bioRxiv.

[4]  K. Kurian,et al.  Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma , 2021, Journal of oncology.

[5]  K. O'Byrne,et al.  Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients , 2021, Frontiers in Oncology.

[6]  E. Shin,et al.  Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients , 2020, Scientific Reports.

[7]  D. Richard,et al.  High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC) , 2020, medRxiv.

[8]  J. W. Kim,et al.  PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer , 2020, Scientific Reports.

[9]  Kyoung-Mee Kim,et al.  PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression , 2020, Cancers.

[10]  F. Roviello,et al.  MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy , 2020, Journal of clinical medicine.

[11]  Chao Chen,et al.  Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets , 2019, bioRxiv.

[12]  Joon-Oh Park,et al.  Bridging genomics and phenomics of gastric carcinoma , 2019, International journal of cancer.

[13]  R. Busuttil,et al.  Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry , 2019, Nature Communications.

[14]  N. Sivaram,et al.  Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer , 2019, The Journal of clinical investigation.

[15]  K. Syrigos,et al.  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling , 2019, Clinical Cancer Research.

[16]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[17]  W. Haining,et al.  PI3K activated tumors evade tumor immunity by promoting an inhibitory myeloid microenvironment , 2019, The Journal of Immunology.

[18]  H. Chung,et al.  Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer , 2019, AntiCancer Research.

[19]  H. Hamana,et al.  Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations , 2019, Cancers.

[20]  Jingting Jiang,et al.  Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer , 2019, Front. Immunol..

[21]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[22]  F. Roviello,et al.  PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[23]  R. Yantiss,et al.  Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features , 2018, The American journal of surgical pathology.

[24]  B. Williams,et al.  Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry , 2017, Journal of Translational Medicine.

[25]  J. Ajani,et al.  Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project , 2017, Clinical Cancer Research.

[26]  Soyeon Ahn,et al.  PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. , 2017, Oncotarget.

[27]  Kyoung-Mee Kim,et al.  Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma , 2016, Gastric Cancer.

[28]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[30]  Li Zhao,et al.  Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RAS , 2010, Cell cycle.

[31]  Li Zhao,et al.  Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.

[32]  A. Marchetti,et al.  Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas , 2007, Clinical Cancer Research.

[33]  Joon-Oh Park,et al.  Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial , 2019 .